

Carcinoid Syndrome - Pipeline Insight, 2021

<https://marketpublishers.com/r/CAD63C9E85FBEN.html>

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: CAD63C9E85FBEN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Carcinoid Syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Carcinoid Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Carcinoid Syndrome Understanding

Carcinoid Syndrome: Overview

Carcinoid syndrome is a disease consisting of a combination of symptoms, physical manifestations, and abnormal laboratory findings. It is also known as carcinoid apudoma, carcinoid cancer, carcinoid disease, and functioning argentaffinoma. The signs and symptoms of carcinoid syndrome depend on which chemicals the carcinoid tumor secretes into your bloodstream. Carcinoid syndrome is caused by a carcinoid tumor that secretes serotonin or other chemicals into your bloodstream. Carcinoid tumors occur most often in the gastrointestinal tract, including your stomach, small intestine, appendix, colon and rectum. The pathophysiology of carcinoid syndrome is based on biologically active amines and peptides entering the systemic circulation and escaping the first-pass metabolism of the liver. Treatment modalities for carcinoid

syndrome, include somatostatin analogs, liver-directed treatment therapy, surgical debulking for early-stage low-grade neuroendocrine tumors, and chemotherapy for the treatment of poorly differentiated neuroendocrine tumors or refractory carcinoid syndrome.

'Carcinoid Syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Carcinoid Syndrome pipeline landscape is provided which includes the disease overview and Carcinoid Syndrome treatment guidelines. The assessment part of the report embraces, in depth Carcinoid Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Carcinoid Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Carcinoid Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Carcinoid Syndrome.

Carcinoid Syndrome Emerging Drugs Chapters

This segment of the Carcinoid Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Carcinoid Syndrome Emerging Drugs

Paltusotine: Crinetics Pharmaceuticals

Paltusotine (CRN 00808) is an oral non-peptide somatostatin receptor 2 agonist. The drug is in Phase I clinical studies for the treatment of acromegaly and in Phase I clinical studies for the treatment of carcinoid syndrome. Crinetics plans to advance paltusotine

into a Phase II trial to treat carcinoid syndrome associated with NETs in 2021.

AQST-305-SF: Aquestive Therapeutics

AQST-305-SF is a sublingual film with octreotide formulation. The drug is in Phase I clinical studies for the treatment of carcinoid syndrome and acromegaly.

Further product details are provided in the report.....

Carcinoid Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Carcinoid Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Carcinoid Syndrome

There are approx. 3+ key companies which are developing the therapies for Carcinoid Syndrome. The companies which have their Carcinoid Syndrome drug candidates in the most advanced stage, i.e. Phase I include, Crinetics Pharmaceuticals.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Carcinoid Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Carcinoid Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Carcinoid Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Carcinoid Syndrome drugs.

Carcinoid Syndrome Report Insights

- Carcinoid Syndrome Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Carcinoid Syndrome Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Carcinoid Syndrome drugs?

How many Carcinoid Syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Carcinoid Syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Carcinoid Syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Carcinoid Syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Crinetics Pharmaceuticals

Aquestive Therapeutics

Entrinsic Biosciences

Key Products

Paltusotine

AQST-305-SF

Eenterade

Contents

Introduction

Executive Summary

Carcinoid Syndrome: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Carcinoid Syndrome – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

Enterade: Entrinsic Biosciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

Paltusotine: Crinetics Pharmaceuticals

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Carcinoid Syndrome Key Companies
Carcinoid Syndrome Key Products
Carcinoid Syndrome- Unmet Needs
Carcinoid Syndrome- Market Drivers and Barriers
Carcinoid Syndrome- Future Perspectives and Conclusion
Carcinoid Syndrome Analyst Views
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Carcinoid Syndrome

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Carcinoid Syndrome

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Carcinoid Syndrome - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/CAD63C9E85FBEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CAD63C9E85FBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970